Bupropion hydrochloride

CLINICAL USE

Adjunct to smoking cessation

DOSE IN NORMAL RENAL FUNCTION

150 mg once daily for 6 days, then twice daily

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :276.2

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :84

%Excreted unchanged in urine &nbsp &nbsp : 0.5

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :2000 litres

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :14–20

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : 150 mg daily

10 to 20 &nbsp &nbsp : 150 mg daily

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : 150 mg daily

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR <10 mL/min

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL/min

HDF/high flux &nbsp :Not dialysed. Dose as in GFR <10 mL/min

CAV/VVHD &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in GFR 10 to 20 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antidepressants: avoid MAOIs and linezolid with and for 2 weeks before starting treatment; avoid concomitant treatment with moclobemide; possibly increased citalopram concentration

Antivirals: concentration increased by ritonavir, risk of toxicity – avoid concomitant use

Ciclosporin: may reduce ciclosporin levels

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Bupropion and metabolites may accumulate in renal failure

Tags: post-by-auto-php